Risk factors
Greenwich LifeSciences (GLSI) risk factors
Item 1A of every Greenwich LifeSciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors65 risks1 new1 dropped1 reworded
The company newly states it will not pay cash dividends, limiting investor returns to potential share-price appreciation.
Filed Jun 01, 2026 - FY2024 10-K risk factors65 risks
Company is focused on developing its cancer immunotherapy product candidate GP2 for breast and other HER2/neu-expressing cancers. Operations are dominated by clinical development risks, reliance on third-party manufacturers, and the need for significant additional capital.
Filed Apr 15, 2025